Amiodarone Rifampicin Drug–Drug Interaction Management With Therapeutic Drug Monitoring
| Autor: | Thijs H Oude Munnink, Anna Demmer, Kris L L Movig, Roel H J Slenter |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Drug Ventricular Dysfunction Right media_common.quotation_subject Drug-drug interaction Amiodarone 030204 cardiovascular system & hematology Pharmacology 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Cytochrome P-450 CYP3A Humans Medicine Drug Interactions Pharmacology (medical) Active metabolite Aged media_common CYP3A4 medicine.diagnostic_test business.industry Prostheses and Implants Therapeutic drug monitoring Drug Monitoring Rifampin Cardiomyopathies business Rifampicin medicine.drug |
| Zdroj: | Therapeutic Drug Monitoring. 40:159-161 |
| ISSN: | 0163-4356 |
| DOI: | 10.1097/ftd.0000000000000487 |
| Popis: | The authors present a case of a 69-year-old man with arrhythmogenic right ventricular cardiomyopathy controlled with amiodarone and an infected orthopedic prosthesis requiring treatment with rifampicin. This combination involves a pharmacokinetic drug-drug interaction leading to subtherapeutic drug concentrations of amiodarone and its active metabolite. The long half-life of amiodarone and its active metabolite in combination with the late onset and offset of cytochrome P4503A (CYP3A4) induction by rifampicin makes this a challenging drug-drug interaction to cope with in clinical practice. Before, during, and after rifampicin treatment, the serum concentrations of amiodarone and its active metabolite were measured and the amiodarone dose was adjusted accordingly. The amiodarone dose required to maintain effective concentrations was 450% of the initial dose. The drug-drug interaction between amiodarone and rifampicin is relevant, both clinically and pharmacokinetically, and can be managed by dose adjustments of amiodarone based on serum concentrations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|